Viral Services
Total Trials
18
As Lead Sponsor
13
As Collaborator
5
Total Enrollment
1,280
NCT02522754
Development of an Intranasal Proteosome Influenza Vaccine
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jan 31, 2002
Completion: Jan 31, 2004
NCT02746211
Influenza Challenge Study in Healthy Volunteers
Start: Jan 31, 2008
Completion: Dec 31, 2008
NCT02522832
Discovering New Treatments for Asthma and COPD. A New Human Rhinvovirus for Human Challenge
Phase: N/A
Start: Jan 31, 2013
Completion: Dec 31, 2014
NCT02525055
Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model
Start: Jan 31, 2014
Completion: Aug 11, 2014
NCT03220048
Study Examining PrEP-001 in Healthy Subjects
Phase: Phase 2
Start: Sep 16, 2015
Completion: Feb 29, 2016
NCT03296917
Study Examining PrEP-001 in Subjects With Asthma
Start: Dec 11, 2015
Completion: Sep 30, 2016
NCT03338556
A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16
Role: Collaborator
Start: Apr 6, 2016
NCT03919591
RSV Study in Adults 60 to 75 Years of Age
Start: Mar 12, 2019
Completion: Jul 11, 2019
NCT04785612
Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults
Start: Nov 10, 2020
Completion: Aug 16, 2021
NCT04740320
COVID-19 SARS-CoV-2 Screening Protocol
Start: Dec 15, 2020
Completion: Jul 9, 2021
NCT04690335
Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine
Start: Dec 29, 2020
Completion: Sep 9, 2021
NCT04865237
SARS-CoV-2 Human Challenge Characterisation Study
Start: Mar 6, 2021
Completion: Jul 11, 2022
NCT04850898
Study of SAB-176 in Healthy Adult Participants
Start: Jun 23, 2021
Completion: Oct 8, 2021
NCT05572450
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
Start: Sep 7, 2022
Completion: Dec 19, 2022
NCT06254820
Dose, Safety, and Pathogenicity of a New Influenza B Strain
Start: Oct 3, 2023
Completion: Feb 8, 2024
NCT06613737
Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
Start: Sep 11, 2024
Completion: Mar 10, 2025
NCT06492564
Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5)
Phase: Early Phase 1
Start: Dec 2, 2024
Completion: Jan 31, 2026
NCT07189806
Longitudinal Phenotyping and Endotyping Study in Adult Patients With Mild, Moderate, or Severe Asthma
Start: Aug 8, 2025
Completion: Aug 8, 2050
Loading map...